Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study
T C(Centre for Research and Technology Hellas), David Oscier(Royal Bournemouth Hospital), Renata Walewska(Dorset HealthCare University NHS Foundation Trust), Candida Vitale(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Ιoannis Kotsianidis(Democritus University of Thrace), Rosa Collado(Hospital General Universitario De Valencia), Juan Marquet(Instituto Cajal), Fátima Mirás(Hospital Universitario 12 De Octubre), Jorge Labrador(Hospital Universitario de Burgos), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), David Allsup(University of Leeds), Luca Laurenti(Sapienza University of Rome), George Vrachiolias(Democritus University of Thrace), Gian Matteo Rigolin, Maria Dimou(National and Kapodistrian University of Athens), Mattia Schipani(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Anna Puiggros(Hospital Del Mar), Gloria Iacoboni(Vall d'Hebron Hospital Universitari), José‐Ángel Hernández‐Rivas(Hospital Universitario Infanta Leonor), Andrea Visentin(University of Padua), Miguel Alcoceba(Instituto de Investigación Biomédica de Salamanca), Jana Zuchnická(University Hospital Ostrava), Eleftheria Hatzimichael(Thomas Jefferson University), Zadie Davis(Royal Bournemouth Hospital), Lucrecia Yáñez(Universidad de Cantabria), Jacopo Olivieri(Ospedale Santa Maria della Misericordia di Udine), Jana Kotašková(Central European Institute of Technology), Eva Gimeno(Hospital Del Mar), Valerio Guarente(University of Perugia), Theodoros P. Vassilakopoulos(National and Kapodistrian University of Athens), Sofia Chatzileontiadou(AHEPA University Hospital), Elisabetta Albi(University of Perugia), Stanislava Mašlejová(Central European Institute of Technology), Martin Šimkovič(Charles University), Eva Minga(Centre for Research and Technology Hellas), Francesca Bacchiarri(University of Siena), Maria Efstathopoulou(Mansoura University), Antigoni Tranidou(Aristotle University of Thessaloniki), Almudena Navarro‐Bailón(Universidad de Salamanca), Zuzana Kubová(University Hospital Olomouc), Carlota Mayor‐Bastida(Hospital Universitario de La Princesa), Andrea Galitzia(Ospedale di Prato Santo Stefano), Iliana Konstantinou(National and Kapodistrian University of Athens), Sara Galimberti(University of Pisa), Sotiria Besikli‐Dimou(Centre for Research and Technology Hellas), Andreas Epameinondas Koumpis(University of Ioannina), Maria Papaioannou(AHEPA University Hospital), David Donaldson(Endometriosis UK), Tereza Shokralla(Charles University), Georgios Karakatsoulis(University of Ioannina)
Cited by 0
Related Papers
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2020|739
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
|The Lancet|2007|679